Ana Beatriz Cazé

Ms. Ana Beatriz Cazé

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Journal of Global Health
Verified
Journal Article
Open access
Ana Beatriz CazéAna Beatriz Cazé
Ana Beatriz Cazé
TCThiago Cerqueira-Silva Cerqueira-Silva
Thiago Cerqueira-Silva Cerqueira-Silva
ABAdriele P Bomfim
Adriele P Bomfim
GSGisley L de Souza
Gisley L de Souza
AAAmanda Ca Azevedo
Amanda Ca Azevedo
VBViviane Sampaio Boaventura
Viviane Sampaio Boaventura
Long COVID has received less attention from the scientific community than acute COVID-19, representing less than 2% of COVID-19 publications in PubMed Clinical Queries (as of August 31, 2022). Consequently, several important aspects remain undefined, such as its prevalence. Long COVID has been reported to affect between 7.5% to 89% of patients [1–4]. However, most […]

16 November 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
FBFábio Vieira de Bulhões
Fábio Vieira de Bulhões
GAGabriele Eliza Assis
Gabriele Eliza Assis
Ana Beatriz CazéAna Beatriz Cazé
Ana Beatriz Cazé
JPJackson Pedro Barros Pereira
Jackson Pedro Barros Pereira
GLGabriela Garcia de Carvalho Laguna
Gabriela Garcia de Carvalho Laguna
RJRoque Aras Júnior
Roque Aras Júnior
Colchicine is an alkaloid traditionally used to treat inflammatory conditions such as gout and familial Mediterranean fever. Currently, there are proposals for the use of this drug in several other situations, such as cardiovascular and liver diseases and diabetes. In this study, the current literature on the potential of colchicine in the treatment of obesity and metabolic syndrome (MS) was evaluated. The inhibitory action of the NLRP3 inflammasome and other processes, such as reductions in the migration and activation of immune system cells, are effects observed in both in vitro studies and animal models related to colchicine, as well as the promotion of mechanisms of the intensification of lipid metabolism, the reduction of tissue fibrosis, and the reduction of serum glucose and triglycerides. These factors are associated with changes in the prognoses of patients with MS, which, together with obesity, has a high association with inflammatory mechanisms for its maintenance and secondary impairments to homeostasis. In humans, clinical research has rarely addressed the use of colchicine in obesity and MS, with only one pilot randomized clinical trial having been conducted, which identified a beneficial anti-inflammatory effect on endothelial function and the process of insulin resistance in this population. However, it is not yet possible to extrapolate its findings and apply its results to a broader context. Given the potential of this “ancient drug” in various pathological contexts and its good tolerability, it is important that its properties continue to be investigated and that more clinical studies be conducted to expand the therapeutic applications of this low-cost substance in patients with obesity and MS.

1 January 2023 in Revista Brasileira de Saúde Materno Infantil
Verified
Journal Article
Open access
PDF file
GLGabriela Garcia de Carvalho Laguna
Gabriela Garcia de Carvalho Laguna
DRDiego Bastos Ribeiro
Diego Bastos Ribeiro
BTBeatriz Rihs Matos Tavares
Beatriz Rihs Matos Tavares
Ana Beatriz CazéAna Beatriz Cazé
Ana Beatriz Cazé
ASAna Clara Silva dos Santos
Ana Clara Silva dos Santos
GBGrasiely Faccin Borges
Grasiely Faccin Borges
Objectives: to describe behavioral changes related to mental health in children and adolescents with Attention Deficit Hyperactivity Disorder during social isolation due to the COVID-19 pandemic. Methods: this is a systematic review conducted under the PRISMA protocol (2020) in the PubMed, SciELO and VHL databases, with a period of 2019-2022. Results: 3,735 studies were screened and ten were selected, according to the eligibility criteria. The sample had 4,688 participants. There was evidence of a worsening of signs and symptoms regarding the mental health of this population, expressed mainly through changes in mood, with increased anxiety, sadness or depressed symptoms, in addition to increased hyperactivity. Behavioral changes also included reduced sleep quality and physical activity, and increased use of digital technologies and screen time. Conclusions: it was described that children and youth groups, especially those with attention deficit hyperactivity disorder, had increased emotional symptoms and conduct problems when compared to before the pandemic, making it possible to recognize the negative repercussions of the changes imposed by it. These factors are important for planning more effective care strategies.

17 September 2022 in medRxiv
Verified
Preprint
Open access
PDF file
Ana Beatriz CazéAna Beatriz Cazé
Ana Beatriz Cazé
TCThiago Cerqueira-Silva Cerqueira-Silva
Thiago Cerqueira-Silva Cerqueira-Silva
ABAdriele Pinheiro Bomfim
Adriele Pinheiro Bomfim
GSGisley Lima de Souza
Gisley Lima de Souza
AAAmanda Canário Andrade Azevedo
Amanda Canário Andrade Azevedo
VBViviane Sampaio Boaventura
Viviane Sampaio Boaventura
Background: There is limited data on the prevalence and risk factors for long COVID, with a shortage of prospective studies with appropriate control groups and adequate sample size. We therefore performed a prospective study to determine the prevalence and risk factors for long COVID. Methods: We recruited patients age ≥ 15 years who were clinically suspected of having acute SARS-CoV-2 infection from September 2020 to April 2021. Nasopharyngeal swabs were collected for RT-PCR 3-5 days post symptom onset. Clinical and sociodemographic characteristics were collected using structured questionnaires from persons positive and negative for SARS-COV-2. Follow-up was performed by telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life. Results: We followed 814 participants (412 COVD-19 positive and 402 COVID-19 negative persons) of whom the majority (741 / 814) had mild symptoms. Both the COVID-19 positive and the COVID-19 negative groups had similar sociodemographic and clinical characteristics, except for the rate of hospitalization (15.8% vs 1.5%, respectively). One month after disease onset, 122 (29.6%) individuals reported residual symptoms in the COVID-19 positive group or the long COVID group versus 24 (6%) individuals in the COVID-19 negative group. In the long COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms which occurred in the acute phase. Compared to recovered patients, female sex, older age and having > 5 symptoms during the acute phase were risk factors for long COVID. Quality of life was evaluated in 102 out of 122 cases of long COVID with 57 (55.9%) reporting an impact in at least one dimension of the EuroQol 5D-3L questionnaire. Conclusion: In this prospective study consisting predominantly of patients with mild disease, the persistence of symptoms after acute disease was highly associated with long COVID-19 (29.6% vs 6% of COVID negative group). The risk factors for long COVID were older age, female sex, and polysymptomatic acute disease.

1 January 2023 in Revista Brasileira de Saúde Materno Infantil
Verified
Journal Article
Open access
PDF file
GLGabriela Garcia de Carvalho Laguna
Gabriela Garcia de Carvalho Laguna
DRDiego Bastos Ribeiro
Diego Bastos Ribeiro
BTBeatriz Rihs Matos Tavares
Beatriz Rihs Matos Tavares
Ana Beatriz CazéAna Beatriz Cazé
Ana Beatriz Cazé
ASAna Clara Silva dos Santos
Ana Clara Silva dos Santos
GBGrasiely Faccin Borges
Grasiely Faccin Borges
Resumo Objetivos: descrever mudanças comportamentais, relacionadas à saúde mental, em crianças e adolescentes com Transtorno de Déficit de Atenção e Hiperatividade durante o isolamento social devido à pandemia da COVID-19. Métodos: trata-se de uma revisão sistemática conduzida sob protocolo PRISMA (2020) nas bases de dados PubMed, SciELO e BVS, com período de 2019-2022. Resultados: foram triados 3.735 estudos e selecionados dez, de acordo com os critérios de elegibilidade. A amostra contou com 4.688 participantes. Evidenciou-se um agravamento de sinais e sintomas quanto à saúde mental dessa população expresso principalmente através de mudanças no estado de humor, com aumento da ansiedade, tristeza ou sintoma deprimido, além do aumento da hiperatividade. As mudanças comportamentais incluíram ainda redução da qualidade do sono e da prática de atividades físicas e aumento do uso de tecnologias digitais e tempo de tela. Conclusões: foi descrito que os grupos infanto-juvenis, sobretudo com Transtorno de Déficit de Atenção e Hiperatividade, tinham sintomas emocionais e problemas de conduta aumentados quando comparados a antes da pandemia, sendo possível reconhecer as repercussões negativas das mudanças impostas por ela. Esses fatores são importantes para o planejamento de estratégias de cuidado mais efetivas.

25 September 2024
Verified
Conference Paper
Open access
CECerón¹
Cerón¹
Ana Beatriz CazéAna Beatriz Cazé
Ana Beatriz Cazé
MSMarco Antônio Silveira²
Marco Antônio Silveira²
MLMarcelo Barreto Lopes³
Marcelo Barreto Lopes³
MAMaria da Conceição Almeida⁴
Maria da Conceição Almeida⁴
ALAntonio Alberto Lopes¹
Antonio Alberto Lopes¹
Introdução: A prevalência de doença renal crônica (DRC) foi demostrada como maior em negros do que em brancos, mas não se tem avaliado se a associação entre raça e DRC varia de acordo com variáveis demográficas e diagnóstico de causas potenciais de DRC e comorbidades prevalentes em pessoas com DRC, como diabetes mellitus (DM) e hipertensão arterial sistêmica (HAS). Objetivo: Estimar se associações de raça e DRC variam na dependência de faixa etária, sexo, HAS e DM. Métodos: Corte transversal da linha de base da coorte multicêntrica do Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil). A amostra incluiu 13.961 participantes da primeira onda do ELSA-Brasil (2008-2010) com dados de raça (pretos, pardos ou brancos) e DRC. Razão albumina/creatinina ≥30 mg/g e/ou TFG < 60 mL/min/1,73m² foram usadas para definir DRC estimada pela equação “CKD epidemiology collaboration”, revista em 2021. Indivíduos autodeclarados como pretos ou pardos foram categorizados como negros. As associações (usando raça branca como referência) foram descritas usando diferença de prevalência (DP) e razão de prevalência (RP), com respectivos Intervalos de Confiança 95% (IC 95%). Variáveis potencialmente modificadoras de efeito incluíram HAS, DM, faixa etária (< 60 anos e ≥ 60 anos) e sexo. Resultados: Dos 13.961 participantes, 6.384 eram negros e 7.577 eram brancos. A mediana de idade foi 51 anos, com maioria feminina (54,1%). A prevalência de DRC foi maior em negros (8,6%) comparado a brancos (6,4%). Na análise de subgrupos, a DP em pontos percentuais foi maior em idade ≥ 60 anos [4,40 (IC 95% 1,65;7,15)] vs < 60 anos [2,48 (IC 95% 1,65;3,31)]; em mulheres [2,60 (IC 95% 1,48; 3,72)] que em homens [1,89 (IC 95% 0,50;3,28)]; e diabéticos [5,13 (IC 95% 1,92;8,33)] do que em não diabéticos [1,89 (IC 95% 0,50;3,28)], p para homogeneidade=0,011. Uma pequena DP de 1,63 foi observada em hipertensos, mas diferença na DP não foi observada em normotensos. Em contraste com DP, uma maior RP foi observada para idade < 60 anos do que ≥60 anos (1,64 vs 1,31) e não hipertensos do que em hipertensos (1,30 vs 1,13). Para DM e sexo, as direções da RP seguiram a mesma direção que a DP. Conclusão: Negros apresentam maior prevalência de DRC e foram observadas variações nas associações entre raça e DRC usando DP e RP. Estes achados do ELSA-Brasil chamam atenção para a importância de considerar variações na RP e DP como medidas de associação de raça com DRC em subgrupos idade, sexo, DM e HAS.